Repros Therapeutics' strategy is to focus on innovative drugs for the treatment of hormonal and reproductive system disorders. Our initial efforts will be based on the anti-hormone small molecule programs, which includes five different drug indications focused in the female health and male hormonal deficiency markets. Collectively, current markets for these products exceed $3 billion. Zonagen was organized in 1987. In October 2002 the company entered an agreement to merge with Lavipharm, which was terminated in March 2003.